辛伐他汀联合参附注射液治疗合并糖尿病的急性心肌梗死患者心力衰竭临床研究

Clinical Study of Simvastatin Combined with Shenfu Injection on Heart Failure in Patients with Acute Myocardial Infarction Complicated with Diabetes

目的:研究并探讨辛伐他汀联合参附注射液治疗合并糖尿病的急性心肌梗死患者心力衰竭的临床疗效。方法:于2012年6月—2014年2月,选取该阶段内本院收治的88例合并糖尿病的急性心肌梗死患者作为此次研究的对象,采取数字随机表法将患者随机分为对比组和实验组,每组44例。对比组采取常规治疗,实验组在常规治疗的基础上加用参附注射液。比较两组患者的血脂水平、左心功能、炎性标志物水平、药物不良反应、远期生存率。结果:治疗后,实验组的总胆固醇、甘油三酯以及低密度脂蛋白胆固醇均较对比组更低(P<0.05),实验组的BNP以及超敏C反应蛋白均较对比组明显更低(P<0.05)。与治疗前相比,治疗后两组患者的左室间隔厚度、左心后壁厚度、左室舒张末期内径以及左室射血分数均明显改善(P<0.05),且两组之间比较,差异均具有统计学意义(P<0.05)。两组患者均未出现明显的不良反应。随访2年发现,实验组的2年生存率为95.45%,较对比组更高。结论:在合并糖尿病且出现心力衰竭的急性心肌梗死患者治疗过程中,给予患者辛伐他汀联合参附注射液治疗,可有效降低患者机体内的血脂水平以及炎性反应,还可有效改善患者的左心功能,提高远期生存率,且安全可靠。

Objective：To study the clinical effect of simvastatin combined with Shenfu Injection on heart failure in patients with acute myocardial infarction complicated with diabetes mellitus. Methods：During February 2012 to June 2014 in our hospital, select 88 cases of diabetes patients with acute myocardial infarction （AMI） as the research object, according to the random number table method, were randomly divided into the contrast group and the experimental group （ n = 44 ）. The contrast group was treated with conventional therapy. The experimental group was treated with Shenfa Injection on the basis of conventional therapy. Blood lipid levels, left ventricular function,inflammatory markers, adverse drug reaction and long - term survival rate were compared between the two groups. Results：After treatment, the experimental group＇s total cholesterol,trig]ycerides and low density lipoprotein choles- terol were lower than those of the contrast group （ P 〈 0.05 ）. In the experimental group, BNP and high - sensitivity C - reactive protein were significantly lower compared with those of the contrast group （ P 〈 0.05）. Compared with those before treatment, after treatment two groups＇ left ventricular septum thickness, left heart wall thickness, left ventricular end diastolic diameter and left ventricular ejection fraction were significantly improved （P 〈 0.05 ） and between the two groups, the differences were statistically significant（ P 〈 0.05 ）. There were no obvious adverse reactions in the two groups. After 2 years of follow - up, the 2 - year surviv- al rate of the experimental group was 95.45% ,higher than that of the contrast group. Conclusion：In diabetes and heart failure of acute myocardial infarction patients in the process, simvastatin and Shenfu Injection can effectively reduce the patients＇ body with- in the lipid levels, the degree of inflammatory reaction, effectively improve the patient＇s left ventricular function, and improve the survival rate, which is safe and reliable.